Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Director | June 20, 2018 | June 22, 2018 |
| CareDx, Inc.CDNA · Entity 4344 | Director | June 12, 2026 | June 16, 2026 |
| FIVE PRIME THERAPEUTICS, INC.FPRX · Entity 16595 | Director | May 10, 2017 | May 12, 2017 |
| Intellia Therapeutics, Inc.NTLA · Entity 4585 | Director | June 09, 2026 | June 10, 2026 |
| Kyverna Therapeutics, Inc.KYTX · Entity 5452 | Director | May 27, 2026 | May 29, 2026 |
| Progyny, Inc.PGNY · Entity 4521 | Director | May 23, 2024 | May 29, 2024 |
| Roka BioScience, Inc.ROKA · Entity 172682 | Director | June 28, 2017 | June 30, 2017 |
| TANDEM DIABETES CARE INCTNDM · Entity 4682 | Director | November 15, 2018 | November 19, 2018 |
| UroGen Pharma Ltd.URGN · Entity 4466 | Director | August 06, 2024 | August 08, 2024 |
| VERACYTE, INC.VCYT · Entity 2018 | Director | October 19, 2020 | October 20, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date June 20, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Automatic Stock Option GrantSEC Table II · derivative / convertible security · Conversion / exercise price $6.09 · Expires 2028-06-20 | Direct | 30,000 |
Reported balance
After 2018-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-20 · Grant · Acquired 30,000 · Balance 30,000 F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2: Vests 1/12th per month over twelve months beginning July 20, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan.
F2: Vests 1/12th per month over twelve months beginning July 20, 2018.
CareDx, Inc.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 165,060 |
Reported balance
After 2026-06-12 transaction · row 1
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 9,795 · Balance 165,060 F1: The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are represented by restricted stock units ("RSUs"), of which the RSUs vests 100% on the earlier of the one year anniversary of grant or the day immediately before the first Annual Meeting that occurs after the grant date., subject to the Reporting Person's continuous service on each applicable vesting date.
FIVE PRIME THERAPEUTICS, INC.
Report date May 10, 2017 · Filed May 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.80 · Expires 2027-05-09 | Direct | 10,000 |
Reported balance
After 2017-05-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-10 · Grant · Acquired 10,000 · Balance 10,000 F1: This option will vest in its entirety on the earlier to occur of (i) May 10, 2018 or (ii) the day before the 2018 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in its entirety on the earlier to occur of (i) May 10, 2018 or (ii) the day before the 2018 annual meeting of stockholders of Five Prime Therapeutics, Inc. (the "Company"), subject to the reporting person's continued service to the Company through such vest date.
Intellia Therapeutics, Inc.
Report date June 09, 2026 · Filed June 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,653 |
Reported balance
After 2026-06-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 9,200 · Balance 216,653 F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.89 · Expires 2036-06-08 | Direct | 13,300 |
Reported balance
After 2026-06-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-09 · Grant · Acquired 13,300 · Balance 13,300 F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
F2: This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Kyverna Therapeutics, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,727 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 5,093 · Balance 21,727 F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.59 · Expires 2036-05-27 | Direct | 20,582 |
Reported balance
After 2026-05-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-27 · Grant · Acquired 20,582 · Balance 20,582 F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,523,924 |
Reported balance
Holding disclosure · report date 2026-05-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,523,924 F3: Shares held directly by Vida Ventures, LLC ("Vida"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award of common stock, which will vest in full on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F2: All of the shares subject to the option shall be fully vested and exercisable on the earlier of (i) May 27, 2027, and (ii) immediately prior to the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive.
F3: Shares held directly by Vida Ventures, LLC ("Vida"). Vida Ventures Advisors, LLC is the investment advisor to Vida. Dr. Arie Belldegrun, Leonard Potter and the Reporting Person are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida, but each disclaims beneficial ownership of the shares held by Vida except to the extent of such person's pecuniary interest therein, if any.
Progyny, Inc.
Report date May 23, 2024 · Filed May 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,693 |
Reported balance
After 2024-05-23 transaction · row 1
1 source rowRow 1 · 2024-05-23 · Grant · Acquired 6,176 · Balance 22,693 F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 23, 2025, subject to the Reporting Person's continued service on such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.15 · Expires 2034-05-22 | Direct | 25,070 |
Reported balance
After 2024-05-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-23 · Grant · Acquired 25,070 · Balance 25,070 F2: The shares subject to the option will vest on May 23, 2025, subject to the Reporting Person's continued service on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Issuer common stock underlying restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs will vest on May 23, 2025, subject to the Reporting Person's continued service on such date.
F2: The shares subject to the option will vest on May 23, 2025, subject to the Reporting Person's continued service on such date.
Roka BioScience, Inc.
Report date June 28, 2017 · Filed June 30, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2027-06-27 | Direct | 3,000 |
Reported balance
After 2017-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-28 · Grant · Acquired 3,000 · Balance 3,000 |
TANDEM DIABETES CARE INC
Report date November 15, 2018 · Filed November 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $33.12 | Direct | 25,000 |
Reported balance
After 2018-11-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-11-15 · Grant · Acquired 25,000 · Balance 25,000 F1: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F2: All shares subject to the option will vest in equal monthly installments over 12 months. F3: The expiration date for these options is 10 years from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan.
F2: All shares subject to the option will vest in equal monthly installments over 12 months.
F3: The expiration date for these options is 10 years from the date of grant.
UroGen Pharma Ltd.
Report date August 06, 2024 · Filed August 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right ot buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.16 · Expires 2034-08-06 | Direct | 10,000 |
Reported balance
After 2024-08-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-06 · Grant · Acquired 10,000 · Balance 10,000 F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year, subject to the director's Continuous Service (as defined in the 2017 Equity Incentive Plan) through such vesting dates.
VERACYTE, INC.
Report date October 19, 2020 · Filed October 20, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,000 |
Reported balance
After 2020-10-19 transaction · row 1
1 source rowRow 1 · 2020-10-19 · Exercise / conversion · Acquired 10,000 · Balance 10,000 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.60 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2020-10-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-19 · Exercise / conversion · Disposed 10,000 · Balance 0 F1: The option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GENOMIC HEALTH INC
Report date November 08, 2019 · Filed November 14, 2019
Section 16 reporting ended · disclosed 2019-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-11-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-11-08 · Disposition to issuer · Disposed 68,165 · Balance 955 F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $1,874,586 and 30,703 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019. Row 2 · 2019-11-08 · Disposition to issuer · Disposed 955 · Balance 0 F2: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Common StockSEC Table I · non-derivative | IndirectBy the Jane K Cohen Trust | 0 |
Reported balance
After 2019-11-08 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-11-08 · Disposition to issuer · Disposed 6,068 · Balance 0 F3: Disposed of in connection with the Merger pursuant to the Merger Agreement, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $166,888 and 2,733 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.87 · Expires 2023-06-07 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-08 · Disposition to issuer · Disposed 8,250 · Balance 0 F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $105,114 and 1,721 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.04 · Expires 2023-06-07 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-08 · Disposition to issuer · Disposed 1,515 · Balance 0 F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $19,197 and 314 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.18 · Expires 2026-06-10 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,281 and 2,739 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.53 · Expires 2027-06-16 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F7: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.72 · Expires 2028-06-07 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-08 · Disposition to issuer · Disposed 10,000 · Balance 0 F8: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.41 · Expires 2029-06-14 | Direct | 0 |
Reported balance
After 2019-11-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-08 · Disposition to issuer · Disposed 6,583 · Balance 0 F9: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $39,074 and 640 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of in connection with the acquisition of Issuer (the "Merger") by Exact Sciences Corporation ("Exact Sciences") pursuant to the Agreement and Plan of Merger, dated July 28, 2019 (the "Merger Agreement"), among Exact Sciences, Spring Acquisition Corp., and Issuer, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $1,874,586 and 30,703 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.
F2: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $26,277 and 430 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F3: Disposed of in connection with the Merger pursuant to the Merger Agreement, whereby such shares of Issuer common stock were cancelled and converted into the right to receive a cash payment of $166,888 and 2,733 shares of Exact Sciences common stock, having a market value of $79.95 per share, based on the closing price of Exact Sciences common stock on November 7, 2019.
F4: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $105,114 and 1,721 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F5: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $19,197 and 314 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F6: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $167,281 and 2,739 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F7: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $145,268 and 2,379 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F8: Disposed of in connection with the Merger, whereby such Issuer stock option was cancelled in exchange for a cash payment of $62,196 and 1,018 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019.
F9: Disposed of in connection with the Merger, whereby such Issuer restricted stock unit award, whether or not vested, was cancelled in exchange for a cash payment of $39,074 and 640 shares of Exact Sciences common stock, having a market value of $79.95 per share based on the closing price of Exact Sciences common stock on November 7, 2019. Pursuant to the applicable option award agreement, 100% of the unvested options held by the Reporting Person became fully vested following the change in control of the Issuer effected by the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2019 Filed May 22, 2019 20:32 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (right to buy) · Derivative | 19,000 | $0.00 Strike: $15.78 | $0.00 |
DisclosureSEC source: 0001209191-19-032076 · doc4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2029-05-20 F1 · derivative.exercise_date: This option was granted on May 21, 2019 with respect to 19,000 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. Read SEC document |
| April 01, 2019 Filed Apr 3, 2019 18:00 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 149 | $66.84 | $9,959.16 |
DisclosureSEC source: 0001209191-19-023405 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,768 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:36 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantCommon Stock | 10,000 | $16.89 | $168,936.00 |
DisclosureSEC source: 0001209191-19-016544 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.85 to $16.93, inclusive. The reporting person will provide to the Securities and Exchange Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 16:49 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $26.01 | $0.00 |
DisclosureSEC source: 0001209191-19-013584 · doc4.xml · derivative · entry 5 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 16:49 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 693 | $79.57 | $55,141.87 |
DisclosureSEC source: 0001209191-19-013584 · doc4.xml · nonDerivative · entry 3 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,619 F1 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $79.50 to $80.02. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 16:49 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 9,307 | $78.80 | $733,416.73 |
DisclosureSEC source: 0001209191-19-013584 · doc4.xml · nonDerivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,312 F1 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $78.42 to $79.37. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 16:49 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionCommon Stock | 10,000 | $26.01 | $260,100.00 |
DisclosureSEC source: 0001209191-19-013584 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,619 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2019 Filed Mar 22, 2019 23:41 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $16.99 | $0.00 |
DisclosureSEC source: 0001209191-19-021091 · doc4.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 15,000 shares Expires 2027-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 6.25% of the ordinary shares underlying the stock option vested on each of August 15, 2017, November 15, 2017 and February 15, 2018; 31.25% of the shares vested on May 15, 2018, and the remaining shares vest in 8 equal quarterly installments thereafter. Read SEC document |
| February 06, 2019 Filed Mar 22, 2019 23:41 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 15,000 | $16.99 | $254,850.00 |
DisclosureSEC source: 0001209191-19-021091 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2019 Filed Jan 24, 2019 22:31 UTC | Intellia Therapeutics, Inc. NTLA · Entity 4585 | GrantStock Option (Right to Buy) · Derivative | 38,000 | $0.00 Strike: $13.78 | $0.00 |
DisclosureSEC source: 0000899243-19-001905 · doc4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires 2029-01-22 F1 · derivative.exercise_date: This option was granted on January 23, 2019 with respect to 38,000 shares of Common Stock, with 33% vesting on January 23, 2020 and the remaining 67% vesting in eight substantially equal quarterly installments thereafter. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 19:13 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 155 | $64.41 | $9,983.55 |
DisclosureSEC source: 0001209191-19-001417 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,619 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| November 15, 2018 Filed Nov 19, 2018 23:22 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Option · Derivative | 25,000 | $0.00 Strike: $33.12 | $0.00 |
DisclosureSEC source: 0001209191-18-059304 · doc4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F2 · derivative.exercise_date: All shares subject to the option will vest in equal monthly installments over 12 months. F3 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 18:27 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $27.75 | $0.00 |
DisclosureSEC source: 0001209191-18-058383 · doc4.xml · derivative · entry 8 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2024-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 18:27 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 403 | $89.50 | $36,068.22 |
DisclosureSEC source: 0001209191-18-058383 · doc4.xml · nonDerivative · entry 6 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,464 F1 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F6 · price: Represents weighted average sale price. Actual sale prices ranged from $89.41 to $89.50. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 18:27 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 4,200 | $88.73 | $372,678.18 |
DisclosureSEC source: 0001209191-18-058383 · doc4.xml · nonDerivative · entry 5 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,867 F1 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F5 · price: Represents weighted average sale price. Actual sale prices ranged from $88.35 to $89.30. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 18:27 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 3,816 | $87.98 | $335,714.51 |
DisclosureSEC source: 0001209191-18-058383 · doc4.xml · nonDerivative · entry 4 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,067 F1 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F4 · price: Represents weighted average sale price. Actual sale prices ranged from $87.35 to $88.34. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 18:27 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 745 | $85.67 | $63,823.48 |
DisclosureSEC source: 0001209191-18-058383 · doc4.xml · nonDerivative · entry 3 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,883 F1 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $85.52 to $86.00. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 18:27 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 836 | $84.90 | $70,977.74 |
DisclosureSEC source: 0001209191-18-058383 · doc4.xml · nonDerivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,628 F1 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $84.48 to $85.30. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 18:27 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionCommon Stock | 10,000 | $27.75 | $277,500.00 |
DisclosureSEC source: 0001209191-18-058383 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:13 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 142 | $70.18 | $9,965.56 |
DisclosureSEC source: 0001209191-18-054153 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,464 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 17:02 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 8,250 | $0.00 Strike: $34.44 | $0.00 |
DisclosureSEC source: 0001209191-18-050301 · doc4.xml · derivative · entry 4 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,250 shares Expires 2022-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 17:02 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 8,250 | $61.51 | $507,453.38 |
DisclosureSEC source: 0001209191-18-050301 · doc4.xml · nonDerivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,322 F1 · price: Represents weighted average sale price. Actual sale prices ranged from $61.33 to $61.76. F2 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. Read SEC document |
| September 06, 2018 Filed Sep 10, 2018 17:02 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionCommon Stock | 8,250 | $34.44 | $284,130.00 |
DisclosureSEC source: 0001209191-18-050301 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2018 Filed Aug 29, 2018 22:09 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0000899243-18-023497 · doc4.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/12th of the shares subject to the option vested on August 13, 2017 and the remaining shares subject to the option vested monthly thereafter through July 13, 2018. Read SEC document |
| August 28, 2018 Filed Aug 29, 2018 22:09 UTC | CareDx, Inc. CDNA · Entity 4344 | Exercise / conversionCommon Stock | 15,000 | $1.22 | $18,300.00 |
DisclosureSEC source: 0000899243-18-023497 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,901 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 19:47 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 8,250 | $0.00 Strike: $25.79 | $0.00 |
DisclosureSEC source: 0001209191-18-046100 · doc4.xml · derivative · entry 5 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,250 shares Expires 2021-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 19:47 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 1,400 | $56.81 | $79,534.98 |
DisclosureSEC source: 0001209191-18-046100 · doc4.xml · nonDerivative · entry 3 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,322 F1 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F3 · price: Represents weighted average sale price. Actual sale prices ranged from $56.65 to $56.92. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 19:47 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | SaleCommon Stock | 6,850 | $56.10 | $384,265.14 |
DisclosureSEC source: 0001209191-18-046100 · doc4.xml · nonDerivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,722 F1 · price: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F2 · price: Represents weighted average sale price. Actual sale prices ranged from $55.65 to $56.64. Read SEC document |
| August 07, 2018 Filed Aug 9, 2018 19:47 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | Exercise / conversionCommon Stock | 8,250 | $25.79 | $212,767.50 |
DisclosureSEC source: 0001209191-18-046100 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,572 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 16:03 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 198 | $50.40 | $9,979.20 |
DisclosureSEC source: 0001209191-18-040923 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,322 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 13:29 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantAutomatic Stock Option Grant · Derivative | 30,000 | $0.00 Strike: $6.09 | $0.00 |
DisclosureSEC source: 0001127602-18-021726 · form4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-20 F1 · security: Automatic non-employee director grant pursuant to the BioCryst Pharmaceuticals, Inc. Stock Incentive Plan. F2 · derivative.exercise_date: Vests 1/12th per month over twelve months beginning July 20, 2018. Read SEC document |
| June 20, 2018 Filed Jul 3, 2018 21:22 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $14.74 | $0.00 |
DisclosureSEC source: 0000899243-18-019262 · doc4.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-06-20 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on July 20, 2018 and the shares subject to the option shall vest monthly thereafter through June 20, 2019. Read SEC document |
| June 20, 2018 Filed Jul 3, 2018 21:22 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019262 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,901 F1 · shares: The reported securities are represented by restricted stock units which shall vest on June 20, 2019. Read SEC document |
| June 07, 2018 Filed Jun 7, 2018 21:08 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $7.60 | $0.00 |
DisclosureSEC source: 0001384101-18-000038 · wf-form4_152840571332258.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-07 F1 · derivative.exercise_date: The option becomes exercisable in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option vests in full in the event of a change in control of the Company. Read SEC document |
| June 07, 2018 Filed Jun 11, 2018 19:55 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantDirector Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $51.72 | $0.00 |
DisclosureSEC source: 0001209191-18-037126 · doc4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-07 F1 · derivative.exercise_date: The option becomes exercisable in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option becomes fully vested in the event of a change in control of the Company. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 20:32 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 319 | $31.29 | $9,981.51 |
DisclosureSEC source: 0001209191-18-023362 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,124 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| January 01, 2018 Filed Jan 3, 2018 18:22 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 292 | $34.20 | $9,986.40 |
DisclosureSEC source: 0001209191-18-001286 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,805 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 23:00 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Option · Derivative | 5,300 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001209191-17-064033 · doc4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,300 Underlying: Common Stock · 5,300 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. The grant is contingent upon future stockholder approval of an increase in the number of shares reserved for issuance under the 2013 Stock Incentive Plan. F2 · derivative.exercise_date: All shares subject to the option will vest in equal monthly installments over twelve (12) months. F3 · derivative.expiration_date: The expiration date for these options is ten (10) years from the date of grant. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 23:47 UTC | TANDEM DIABETES CARE INC TNDM · Entity 4682 | GrantStock Options · Derivative | 1,700 | $0.00 Strike: $2.54 | $0.00 |
DisclosureSEC source: 0001209191-17-061618 · doc4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Underlying: Common Stock · 1,700 shares Expires not disclosed F1 · security: Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan. F2 · derivative.exercise_date: All shares subject to the option will vest in equal monthly installments over 12 months. F3 · derivative.expiration_date: The expiration date for these options is 10 years from the date of grant. Read SEC document |
| November 09, 2017 Filed Nov 13, 2017 21:10 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantOption to Purchase Common Stock · Derivative | 6,679 | Not disclosed Strike: $5.49 | Not disclosed |
DisclosureSEC source: 0000899243-17-026018 · doc4.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,679 Underlying: Common Stock · 6,679 shares Expires 2024-11-09 F3 · security: Represents a stock option granted pursuant to the Exchange Offer (the "New Options"). F4 · derivative.exercise_price: The exercise price per share equals the closing price per share of the Company's common stock, as quoted by NASDAQ, on November 9, 2017. F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 10,948 shares granted to the reporting person on June 19, 2014. In exchange for such cancelled stock option, the reporting person received a new stock option for 6,679 shares. F5 · derivative.exercise_date: The New Options are scheduled to vest in three equal installments based upon the Company's achievement of certain performance goals as follows: (i) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved $10 million of total cumulative sales of Allosure, its proprietary next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing after the completion of the Exchange Offer, (ii) one third of the New Options vest upon the Company's determination, which has been reviewed by the Company's independent registered public accounting firm, that the Company has achieved quarterly revenues of at least $18.75 million for two consecutive fiscal quarters commencing after the completion of the Exchange Offer, F6 · derivative.exercise_date: (Continued from Footnote 5) and (iii) one third of the New Options vest in the event the closing sales price of the Company's common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after the completion of the Exchange Offer. Read SEC document |
| November 08, 2017 Filed Nov 13, 2017 21:10 UTC | CareDx, Inc. CDNA · Entity 4344 | Disposition to issuerOption to Purchase Common Stock · Derivative | 10,948 | Not disclosed Strike: $12.40 | Not disclosed |
DisclosureSEC source: 0000899243-17-026018 · doc4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,948 shares Expires 2024-06-19 F2 · price: On November 8, 2017, pursuant to the offer by CareDx, Inc. (the "Company") to exchange certain outstanding stock options for new options as more fully described in the Schedule TO-I, filed with the Securities Exchange Commission on October 12, 2017, as amended and supplemented on October 24, 2017 and November 9, 2017(the "Exchange Offer"), the Company cancelled a stock option for 10,948 shares granted to the reporting person on June 19, 2014. In exchange for such cancelled stock option, the reporting person received a new stock option for 6,679 shares. F1 · derivative.exercise_date: The shares underlying the cancelled option were vested and immediately exercisable. Read SEC document |
| October 01, 2017 Filed Oct 3, 2017 18:16 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 311 | $32.09 | $9,979.99 |
DisclosureSEC source: 0001209191-17-055382 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,513 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 14:07 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionNon-Qualified Stock Option · Derivative | 54,250 | $0.00 Strike: $4.27 | $0.00 |
DisclosureSEC source: 0001127602-17-027802 · form4.xml · derivative · entry 3 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 54,250 shares Expires 2017-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · date: This transaction was made due to the upcoming expiration of the option. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 14:07 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 54,250 | $5.42 | $294,035.00 |
DisclosureSEC source: 0001127602-17-027802 · form4.xml · nonDerivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,410 F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $5.40 to $5.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| September 18, 2017 Filed Sep 20, 2017 14:07 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 54,250 | $4.27 | $231,647.50 |
DisclosureSEC source: 0001127602-17-027802 · form4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 13, 2017 Filed Jul 14, 2017 21:13 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantStock Option (right to buy) · Derivative | 15,000 | $1.22 Strike: $1.22 | $18,300.00 |
DisclosureSEC source: 0000899243-17-018284 · doc4.xml · derivative · entry 2 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-07-13 F2 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest on August 13, 2017 and the shares subject to the option shall vest monthly thereafter through July 13, 2018. Read SEC document |
| July 13, 2017 Filed Jul 14, 2017 21:13 UTC | CareDx, Inc. CDNA · Entity 4344 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-018284 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,901 F1 · shares: The reported securities are represented by restricted stock units which shall vest on July 13, 2018. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 19:03 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantCommon Stock | 307 | $32.55 | $9,992.85 |
DisclosureSEC source: 0001209191-17-043733 · doc4.xml · nonDerivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,202 F1 · security: Restricted stock issued to the Reporting Person pursuant to the Genomic Health, Inc. 2005 Stock Incentive Plan in lieu of quarterly director retainer fees. Restricted stock is fully vested. Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 13:27 UTC | Roka BioScience, Inc. ROKA · Entity 172682 | GrantStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001472343-17-000044 · wf-form4_149882924790794.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2027-06-27 Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 20:38 UTC | GENOMIC HEALTH INC GHDX · Entity 153816 | GrantDirector Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $31.53 | $0.00 |
DisclosureSEC source: 0001209191-17-041149 · doc4.xml · derivative · entry 1 Cohen Fred E · CIK 0001339358 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-16 F1 · derivative.exercise_date: The option becomes exercisable in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the option becomes fully vested in the event of a change in control of the Company. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.